|Bid||9.19 x 3100|
|Ask||0.00 x 3200|
|Day's Range||8.98 - 9.28|
|52 Week Range||7.60 - 14.20|
|Beta (3Y Monthly)||2.21|
|PE Ratio (TTM)||N/A|
|Earnings Date||Oct 31, 2019|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||14.43|
Ironwood Pharmaceuticals, Inc. (IRWD) today announced it will host its third quarter 2019 investor update conference call and webcast at 8:30 a.m. Eastern Time on Thursday, October 31, 2019. Individuals interested in participating in the call should dial (866) 393-4306 (U.S. and Canada) or (734) 385-2616 (international) using conference ID number 1683099. To access the webcast, please visit the Investors section of Ironwood’s website at www.ironwoodpharma.com at least 15 minutes prior to the start of the call to ensure adequate time for any software downloads that may be required.
Today we'll do a simple run through of a valuation method used to estimate the attractiveness of Ironwood...
Ironwood (IRWD) announces amendment in collaboration agreement with AstraZeneca, granting the latter exclusive rights to develop, manufacture and commercialize Linzess in China.
The following is a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks that hit 52-week highs on Sept. 17.) 10X Genomics Inc (NASDAQ: TXG ) (listed ...
Ironwood Pharmaceuticals, Inc. (IRWD), a GI healthcare company, announced today that it has amended its collaboration agreement with AstraZeneca for the development and commercialization of LINZESS in China. LINZESS was approved by the National Medical Products Administration for adults with IBS-C in China in January 2019.
Ardelyx (ARDX) gets first-ever FDA approval for its pipeline candidate, tenapanor, as a treatment for irritable bowel syndrome with constipation in adults. It will be available under the tradename Ibsrela.
Legendary fund manager Li Lu (who Charlie Munger backed) once said, 'The biggest investment risk is not the volatility...
Ironwood (IRWD) delivered earnings and revenue surprises of 214.29% and 12.75%, respectively, for the quarter ended June 2019. Do the numbers hold clues to what lies ahead for the stock?
Ironwood (IRWD) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
If you're interested in Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD), then you might want to consider its beta (a...